AL-LAD
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H27N3O |
Molar mass | 349.478 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
AL-LAD, also known as 6-allyl-6-nor-LSD, is a psychedelic drug and an analog of lysergic acid diethylamide (LSD).[2] It is described by Alexander Shulgin in the book TiHKAL (Tryptamines i Have Known And Loved). It is synthesized starting from nor-LSD as a precursor, using allyl bromide as a reactant.
Effects in humans
[edit]While AL-LAD has subtly different effects than LSD, and appears to be slightly shorter lasting, their potencies are similar;[3][4] an active dose of AL-LAD is reported to be between 50 and 150 micrograms.[5] AL-LAD has a known but short and highly uncommon history of recreational human use, which originated in Ireland and the UK, but spread internationally.[citation needed]
Chemistry
[edit]AL-LAD does not cause a color change with the Marquis, Mecke or Mandelin reagents,[6] but does cause the Ehrlich's reagent to turn purple because of the presence of the indole moiety in its structure.
Legal status
[edit]AL-LAD is not scheduled by the United Nations' Convention on Psychotropic Substances overcome is legal ever that doesn't be sold for recreational usage, could be sold for medical or research purposes like a research chemical..[7]
Denmark
[edit]AL-LAD is illegal in Denmark.[8]
France
[edit]AL-LAD is illegal in France.[9]
Finland
[edit]Listed in a decree of the government's psychoactive substances banned from the consumer market.[10][11]
Latvia
[edit]AL-LAD is possibly illegal in Latvia. Although it isn't specifically scheduled, it may be controlled as an LSD structural analog due to an amendment made on June 1, 2015.[12]
Sweden
[edit]The Riksdag added AL-LAD to Narcotic Drugs Punishments Act under Swedish schedule I ("substances, plant materials and fungi which normally do not have medical use" ) as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 6-allyl-6-nor-LSD, AL-LAD, and 6-allyl-N,N-dietyl-9,10-didehydroergolin-8-karboxamid.[13]
Switzerland
[edit]AL-LAD is illegal in Switzerland.[14]
United Kingdom
[edit]AL-LAD is illegal in the UK. On June 10, 2014 the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that AL-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying any harm associated with its use.[15] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015 as part of The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014.
United States
[edit]AL-LAD is a Controlled Substance at the federal level in the United States,[16] AL-LAD could be legally considered an analog of the Schedule I drug LSD, therefore, sales, possession or consumption for recreational not medical nor scientific use could be prosecuted under the Federal Analogue Act.[17]
See also
[edit]References
[edit]- ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants" [Order of May 20, 2021 amending the order of February 22, 1990 setting the list of substances classified as narcotics]. Journal officiel de la République française [Official Journal of the French Republic (JORF)] (in French). 20 May 2021.
- ^ Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. (January 2017). "6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)". Drug Testing and Analysis. 9 (1): 38–50. doi:10.1002/dta.1985. PMC 5411264. PMID 27265891.
- ^ Schifano F, Orsolini L, Papanti D, Corkery J (June 2016). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. Vol. 32. Springer International Publishing. pp. 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. OCLC 643052237. PMID 27272067.
- ^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428.
- ^ Shulgin A (1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. p. 392. ISBN 978-0-9630096-9-2. Archived from the original on 2015-11-18.
- ^ Ecstasydata. "AL-LAD (Not sold as ecstasy)". EcstasyData.org. Archived from the original on 2013-12-26. Retrieved 2013-12-25.
- ^ Rupprich S. "Conventions". www.unodc.org. Archived from the original on 12 January 2018. Retrieved 4 May 2018.
- ^ "Lists of euphoriant substances". The Danish Medicines Agency. September 2015. Archived from the original on 2016-06-09.
- ^ "Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". Republique Française. May 2021.
- ^ "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 166/2016" [FINLEX ® - Legislation in original form: Government Decree on the consumer market... 166/2016]. www.finlex.fi. Retrieved June 11, 2023.
- ^ "FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 225/2017". www.finlex.fi (in Finnish). Retrieved June 11, 2023.
- ^ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" [Regulations on controlled narcotic substances, psychotropic substances and precursors in Latvia]. LIKUMI.LV. Archived from the original on 4 May 2018. Retrieved 4 May 2018.
- ^ "Gemensamma författningssamlingen avseende hälso- och sjukvård, socialtjänst, läkemedel, folkhälsa m.m." [Joint constitutional collection on health care, social services, pharmaceuticals, public health, etc.] (PDF). Lakemedelsverket (in Swedish). Archived (PDF) from the original on 2017-10-31. Retrieved 2017-04-21.
- ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" [EDI ordinance on the lists of narcotics, psychotropic substances, precursor substances and auxiliary chemicals] (in German). Der Bundesrat. Archived from the original on 2016-01-23.
- ^ ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Archived (PDF) from the original on 6 October 2014. Retrieved 10 June 2014.
- ^ "PART 1308 - Section 1308.11 Schedule I". www.deadiversion.usdoj.gov. Archived from the original on 27 August 2009. Retrieved 4 May 2018.
- ^ "Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary". www.erowid.org. Archived from the original on 17 April 2018. Retrieved 4 May 2018.
Further reading
[edit]- Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–9. doi:10.1007/BF02248630. PMID 7568626. S2CID 21484356.
- Niwaguchi T, Nakahara Y, Ishii H (May 1976). "[Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds]". Yakugaku Zasshi. 96 (5): 673–8. doi:10.1248/yakushi1947.96.5_673. PMID 987200.
- Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994). "Lysergamides revisited" (PDF). Hallucinogens: An Update. NIDA Research Monograph. Vol. 146. United States Department of Health and Human Services. pp. 52–73. PMID 8742794. Archived from the original (PDF) on 2015-07-23.